Latest Breaking News On - Vial access needle - Page 1 : comparemela.com

Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

/PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior.

Heron Therapeutics Submits Prior Approval Supplement To FDA For Zynrelef VAN

(RTTNews) - Heron Therapeutics, Inc. (HRTX) announced on Wednesday that it has submitted a Prior Approval Supplement or PAS Submission to the FDA .

Heron Therapeutics Is Out Of Survival Mode (NASDAQ:HRTX)

Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

/PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration.

FDA Expands Bupivacaine and Meloxicam (Zynrelef) Approval to Include Additional Orthopedic and Soft Tissue Procedures

On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.